StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) stock

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.75+0.01 (+1.90%)

Close on Nov 20, 2026Market cap $1.38MP/E –Yield –

HCW Biologics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

HCW Biologics's revenue for the twelve months ending Jun 30, 2026 was $6.66M, up 700.2% year over year. For fiscal 2025 it was $54.23K, down 97.9% from the year before. The highest annual figure on record is $6.72M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$54.23K-97.9%
FY2024Dec 31, 2024$2.57M-9.7%
FY2023Dec 31, 2023$2.84M-57.7%
FY2022Dec 31, 2022$6.72M–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$4.10M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$121.73K+1758.5%
Q1 FY2026Mar 31, 2026$6.50M+128231.7%
Q4 FY2025Dec 31, 2025$27.01K-93.2%
Q3 FY2025Sep 30, 2025$15.61K-96.3%
Q2 FY2025Jun 30, 2025$6.55K-98.9%
Q1 FY2025Mar 31, 2025$5.07K-99.6%
Q4 FY2024Dec 31, 2024$394.80K-70.2%
Q3 FY2024Sep 30, 2024$426.42K-50.0%
Q2 FY2024Jun 30, 2024$618.85K-0.6%
Q1 FY2024Mar 31, 2024$1.13M+2590.1%
Q4 FY2023Dec 31, 2023$1.32M-1.3%
Q3 FY2023Sep 30, 2023$853.10K-52.8%
Q2 FY2023Jun 30, 2023$622.81K+37.2%
Q1 FY2023Mar 31, 2023$41.88K-98.7%
Q4 FY2022Dec 31, 2022$1.34M–
Q3 FY2022Sep 30, 2022$1.81M–
Q2 FY2022Jun 30, 2022$454.00K–
Q1 FY2022Mar 31, 2022$3.12M–
Q4 FY2021Dec 31, 2021$0-100.0%
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$0–
Q4 FY2020Dec 31, 2020$4.10M–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–

More HCW Biologics figures

See a number that looks wrong?